Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 4, 2026Advances in Kidney Disease and Health

Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does intensive blood pressure lowering and use of newer antihypertensive agents improve cardiorenal outcomes in patients with advanced chronic kidney disease?

Population

Patients with advanced chronic kidney disease and hypertension

Design

Review

Key result

Newer antihypertensive therapies have proven cardiorenal benefits, but evidence for intensive blood pressure lowering remains limited in patients with advanced chronic kidney disease.

Authors

ETEkamol TantisattamoEKElaine Ku

Discussion

Loading...

Member takes

Overview

Intensive BP lowering in advanced CKD lacks consistent trial support; leaves open optimal targets for practice and dedicated RCTs.

Key Points

  • Investigate the benefits and risks of intensive blood pressure control in advanced chronic kidney disease patients.
  • Overview of trial-grade evidence for antihypertensive agents
  • Focus on cardiorenal outcomes
  • Discussion of evolving therapies from renin-angiotensin inhibitors to newer agents
  • Intensive blood pressure lowering has inconsistent benefits for kidney and cardiovascular health
  • Newer therapies show promise but have limited evidence in advanced CKD
  • Further studies required to assess risks and benefits in this high-risk population

Structured PICO

Does intensive blood pressure lowering and use of newer antihypertensive agents improve cardiorenal outcomes in patients with advanced chronic kidney disease?

P
Population
Patients with advanced chronic kidney disease and hypertension
I
Intervention
Intensive blood pressure lowering and use of newer antihypertensive agents (SGLT2 inhibitors, nonsteroidal aldosterone antagonists, and GLP-1 agonists)
O
Outcome
Cardiorenal outcomes

While newer antihypertensive therapies offer proven cardiorenal benefits, further studies are needed to establish their safety and efficacy specifically in patients with advanced chronic kidney disease.

Limitations

  • Evidence for newer therapies remains limited in patients with advanced chronic kidney disease
  • Evidence for newer therapies remains limited in patients with advanced CKD
  • Patients with advanced CKD are at high risk for adverse side effects from antihypertensive therapy

Cite This Study

Tantisattamo et al. (2026) conducted a review in Hypertension in advanced chronic kidney disease. Intensive blood pressure lowering and newer antihypertensive therapies was evaluated. Newer antihypertensive therapies have proven cardiorenal benefits, but evidence for intensive blood pressure lowering remains limited in patients with advanced chronic kidney disease.

synapsesocial.com/papers/6a48abc789561a0c2d78f0abhttps://doi.org/10.1053/j.akdh.2026.02.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BLOOD PRESSURE LEVELS AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW2025
  2. 2OPTIMIZING ANTIHYPERTENSIVE THERAPY IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS: A REVIEW OF DOSE ADJUSTMENTS AND CLINICAL CONSIDERATIONS2025
  3. 3Evaluating the Renal Implications of Intensive Versus Standard Blood Pressure Control in Chronic Kidney Disease: A Systematic Review of Randomized Trials2025
  4. 4Pros and cons of lower blood pressure targets in chronic kidney disease2025
  5. 5Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies2025